Back to Archived Journals » Open Access Bioinformatics » Volume 3

Molecular-docking study of capsular regulatory protein in Streptococcus pneumoniae portends the novel approach to its treatment

Authors Thapa S, Zubaer

Published 21 December 2011 Volume 2011:3 Pages 131—137

DOI https://doi.org/10.2147/OAB.S26236

Review by Single anonymous peer review

Peer reviewer comments 3



Simrika Thapa1,2, Abdullah Zubaer1,2
1Swapnojaatra Bioresearch Laboratory, DataSoft Systems, Dhaka, Bangladesh, 2Department of Genetic Engineering and Biotechnology, Shahjalal University of Science and Technology, Sylhet, Bangladesh

Abstract: Streptococcus pneumoniae is the major pathogen that causes pneumonia in the pediatric population in Bangladesh and other developing countries. The capsule of this pathogen is the main virulent factor, the synthesis being governed by the capsular polysaccharide gene cluster that encodes for regulatory proteins such as CpsB. Studies have suggested CpsB to be a potential drug target in case of a high rate of vaccine failure as vaccines are intended to target only a few serotypes among 90 available ones. Thus the protein-targeted drug against CpsB is a good alternative to protect against pneumonia. In this study, homology modeling and validation of this protein was performed with certain bioinformatic tools which facilitate the execution of molecular docking against the ligands from the ZINC database. The two potential ligands bind substantially in the active site of this regulatory protein with considerable binding energy in the docking study, which means they could be considered good inhibitors. This study aims to understand the functional aspects of this and also to examine the development of a novel drug against pneumonia.

Keywords: CpsB, drug target, homology modeling, docking, S. pneumoniae

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.